High-Throughput Dried Blood Spot (HT-DBS) Technologies in SARS COV-2 Serology and Vaccinology

项目摘要 随着新冠肺炎大流行继续在美国蔓延，我们必须实施 对大范围人群进行SARS-CoV-2抗体筛查的技术。 血清学监测不仅提供了一种衡量整个社区内病毒暴露的方法，而且还 提供预测疫情动态所需的信息。此外，由于我们对如何 体液因素有助于控制(并可能加剧)新冠肺炎，因此有必要 方法测量与天然SARS-CoV-CoV相关的抗体的“量”和“质”。 2暴露和SARS-CoV-2候选疫苗。这项U01提案旨在促进干血的使用 斑点(DBS)与基于Luminex的微球免疫分析(MIA)相结合，实现高通量 (H)SARS-CoV-2全人群血清学监测。具体地说，该提案将扩大HT- DBS试验捕捉SARS-CoV-2抗体应答的广度和复杂性 感染，并开发高通量竞争免疫分析(CIA)作为SARS的替代措施- DBS中的CoV-2中和抗体效价。建议的平台技术在 沃兹沃斯中心将直接为美国国家通信公司的“…”使命做出贡献开发、验证、改进和实施 血清学检测及相关技术…“以应对新冠肺炎大流行。

Project Summary As the COVID-19 pandemic continues to spread across the United States it is imperative that we implement technologies to screen large swaths of the population for the presence of antibodies to SARS-CoV-2. Serological surveillance not only affords a measure of virus exposure within a community at large but also provides information necessary to predict outbreak dynamics. Furthermore, as our understanding of how humoral factors contribute to controlling (and possibly exacerbating) COVID-19, it will be essential to have methods in place to measure the “quantity” and “quality” of antibodies associated with both natural SARS-CoV- 2 exposure and candidate SARS-CoV-2 vaccines. This U01 proposal seeks to advance the use of dried blood spots (DBS) in conjunction with a Luminex-based microsphere immunoassay (MIA) to enable high-throughput (HT) population-wide serological surveillance for SARS-CoV-2. Specifically, the proposal will expand the HT- DBS assay to capture the breadth and complexity of SARS-CoV-2 antibody responses following natural infection, and develop a high-throughput competitive immunoassay (CIA) as a surrogate measure of SARS- CoV-2 neutralizing antibody titers in DBS. The proposed platform technologies to be developed at the Wadsworth Center will contribute directly to NCI’s mission to “… develop, validate, improve and implement serological testing and associated technologies…” to address the COVID-19 pandemic.